![Jack Lawler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 4 000 $ am 31.05.2026
Mr. Jack Lawler is a Chief Development Officer at Chemomab Therapeutics Ltd. Mr. Lawler was previously employed as a VP-Clinical Operations & Data Management by Goldfinch Bio, Inc. He received his undergraduate degree from Rosemont College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.03.2026 | 40’000 ( 0.01% ) | 4 000 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Corporate Officer/Principal | 15.04.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
Goldfinch Bio, Inc.
 Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 3 |
|---|---|
Rosemont College
 Rosemont College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Goldfinch Bio, Inc.
Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease | Health Technology |
Chemomab Therapeutics Ltd.
 Chemomab Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotech company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
